You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. N/A

    SBC: SRS Technologies            Topic: N/A

    N/A

    STTR Phase II 2000 Department of DefenseDefense Advanced Research Projects Agency
  2. N/A

    SBC: TIME DOMAIN CORP.            Topic: N/A

    N/A

    STTR Phase II 2000 Department of DefenseDefense Advanced Research Projects Agency
  3. Non-invasive delivery of skin-targeted tetanus vaccines

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION: (Adapted from Applicant's Abstract) A major limitation with the contemporary vaccination program as a preventative measure against tetanus is the encumbrance associated with multiple needle-dependent injections. Our aim is to develop a simple method for the delivery of tetanus vaccines by topical application of an adenovirus-vectored vaccine patch. The hyp ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  4. NOVEL DOXORUBICIN ANALOGS:CARDIAC AND CYTOTOXIC EFFECTS

    SBC: GEM Pharmaceuticals            Topic: N/A

    Anthracyclines such as doxorubicin and daunorubicin are valuable anti- cancer drugs but their clinical utility is compromised by cumulative dose-dependent by a cumulative dose dependent cardiotoxicity. Anthracycline cardiotoxicity has been linked to free radical damage via mechanisms that involve disruption of iron regulation and formation of superoxide anion. Although the quinone moiety of anthra ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  5. New Broad Band Rare-Earth-Doped Glasses For Optical Fiber Communications

    SBC: KIGRE, INC.            Topic: BMDO01T001

    Kigre is developing new scalable high gain broad band rare earth doped laser oscillator/amplifier glass materials & diode pump architectures in support of high energy and high power laser applications. What's new, exciting and different about Kigre's laser glass materials and constructs is the ability to efficiently store and extract 1000-10,000x more laser power from ultra-short gain lengths and ...

    STTR Phase II 2004 Department of DefenseDefense Advanced Research Projects Agency
  6. Medication Dispenser: MD2: Improving Health Outcomes

    SBC: INTERACTIVE MEDICAL DEVELOPMENT, LC            Topic: N/A

    DESCRIPTION (provided by investigator): The medication dispensing and monitoring system, MD 2, has been shown in preliminary studies to support a medication compliance rate of 98.5% The MD 2 was developed by Interactive Medical Developments LC to address issues of medicine non-compliance and the negative impact non-compliance has on the health and well being of the patient and the frustration of c ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Novel accelerated in vitro breeding for phytoremediation

    SBC: SOUTHERN SUN BIOSYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term goal of the collaboration between the USC and Southern Sun BioSystems is to create a plant breeding and remediation technology-development center which would supply hardware, protocols for breeding-selection and mass production of elite plants for nurseries and remediation businesses, with licensing and tracking mechanisms for protecting intellect ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Aptamers for Imaging and Therapy

    SBC: Aptalogic, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Phase I The current proposal describes the selection of an aptamer that recognizes the drug PD173955, which is one of large family of substituted pyrido[2,3-d]pyrimidine inhibitors of tyrosine protein kinases. An aptamer is a single stranded nucleic acid that acts like an antibody but that can be expressed and function inside cells. The PD173955 RNA aptamer wi ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  9. MRI Quantification of Postinfarct Myocardial Viability

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this Phase II project is to develop a novel R1-based method for MRI quantification of postinfarct myocardial viability using a commercially available contrast agent Gd(DTPA). The commercial embodiment of this method will be a software package that will convert a set of 2D cardiac MRI images to a 3D myocardial viability map, the Percent Infa ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Cancer dual-targeting of an infectivity-enhance CRAd

    SBC: VECTORLOGICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Studies of the molecular mechanisms underlying neoplastic transformation and progression have resulted in the understanding that cancer is a genetic disease, deriving from the accumulation of a series of acquired genet ic lesions. Despite advances in chemotherapy, radiation delivery, and surgical treatment regimens, survival from many advanced cancers remains ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government